MIMETAS, a leader in human 3D disease modelling, and Yamaha Motor Co., a developer of the Cell Handler, have singed a strategic joint marketing agreement aimed at advancing therapeutic development using human-relevant models throughout the early drug development pipeline. The collaboration combines MIMETAS’ comprehensive disease modelling and assay development expertise with Yamaha Motor’s state-of-the-art Cell […]

Verici Dx, a developer of advanced clinical diagnostics for organ transplant, has signed an exclusive global licensing agreement with Thermo Fisher Scientific to further develop an assay for pre-transplant prognostic testing for risk of early kidney rejection.

Nanologica expands its product portfolio of purification medias for preparative chromatography and has received a trial order worth approximately MSEK 3.6 from a customer in Asia.

The protein alpha-synuclein (aSN) has long been known as a main cause in Parkinson’s disease and Lewy Body Dementia, for example, when it forms lumpy protein aggregates that destroy cell function – but aSN in its natural form, without clumping, has not had a concrete, known function.

Semarion, a University of Cambridge spin-out company from the Cavendish Laboratory combining materials engineering and cell biology to tackle unmet drug screening needs, announced the opening of its Early Adopter Programme for its SemaCyte Microcarrier Platform. The platform overcomes current limitations associated with adherent cell culture and assaying workflows by enabling small colonies of cells […]